Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
-
Industry
-
Biotechnology Research
-
Company size
-
51-200 employees
-
Headquarters
-
Emeryville, California
-
Type
-
Public Company
-
Founded
-
2018
-
Specialties
-
cell therapy, autoimmune, lupus, multiple sclerosis, systemic sclerosis, scleroderma, myasthenia gravis, CAR T-cell, and stiff-person syndrome